Phase I/II trial of subcutaneous decitabine maximizing genomic demethylation in patients with myelodysplastic syndrome

Trial Profile

Phase I/II trial of subcutaneous decitabine maximizing genomic demethylation in patients with myelodysplastic syndrome

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2015

At a glance

  • Drugs Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 01 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 27 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top